Salary Range: 70000 to 110000 (Currency: USD) (Pay period: per-year-salary)

Korro is a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. Korro’s lead program is for Urea Cycle Disorders. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com. 

We are collaborative and united by a common mission. We are building a company with extraordinary people with an audacious vision to create transformative genetic medicines for prevalent diseases. Our values - Rewrite the future, On the Cutting Edge, Better Together, Dynamically Different, Kindness and Integrity form the fabric of the organization. They are reinforced daily and serve as key dimensions in the hiring process to help us ensure that Korro is a magnet for outstanding talent and a great place to work. Join us as we redefine what's possible in genetic medicine and work to make a lasting impact on human health.

Position Summary

Korro Bio is seeking a motivated, detail-oriented Research Associate to join our Oligonucleotide Chemistry team. The successful candidate will synthesize, purify, and characterize chemically modified oligonucleotides and conjugates on automated platforms, supplying oligonucleotides for screening across Korro’s discovery programs. This is a hands-on, lab-based role suited to someone with practical oligonucleotide synthesis experience who takes ownership of instrument operation and maintenance, keeps meticulous records, and communicates results clearly to the team and cross-functionally. This position reports to Scientist II and is based on-site in Cambridge, MA.

Key Responsibilities

Execute solid-phase synthesis, purification, and downstream processing of chemically modified oligonucleotides and oligonucleotides conjugates at different scales using modern automated oligo synthesis platforms

Operate, maintain & troubleshoot equipment for oligonucleotide synthesis (Mermade 12 and 192), purification, desalting and lyophilization

Ability to cross-train with other synthesis scales and instrumentation

Maintain inventory of chemicals and amidites for oligonucleotide synthesis

Perform in-process and final analytics of oligonucleotide samples as needed

Track progress, analyze, organize, and present data to team and cross-functionally

Maintain a well-documented electronic laboratory notebook

Actively participate in training activities and provide training to others as needed

Author and review SOPs and technical reports

Required Qualifications

BS/MS with 1+ years experience in Chemistry, Biochemistry, Biotechnology, or related field

Hands-on experience in the synthesis, purification, and analysis of oligonucleotides

Experience with high throughput synthesizers such as Mermade 192 is a plus

Strong laboratory skills and experience in handling, troubleshooting and routine maintenance of lab equipment including automated synthesis platforms, HPLC and LC-MS etc.

High degree of flexibility and self-motivation in a fast-paced work environment with excellent organizational skills, ability to prioritize appropriately and meet deadlines.

Excellent interpersonal, communication and presentation skills.

Detail-oriented and excellent problem-solving abilities.

Korro Bio offers a competitive total rewards package, including equity-based compensation and comprehensive benefits: medical, dental, and vision coverage; 401(k) retirement plan; life insurance; dependent care flexible spending account; company-funded health savings account; and complimentary parking or a MBTA commuter pass.

About the company

Korro Bio develops RNA-based therapies using RNA editing to modify protein function, aiming to treat serious diseases with few or no current options. The approach targets RNA itself, enabling single base edits in transcripts to change how proteins work, which can adjust disease pathways without altering the DNA. These therapies are intended to be developed and brought to market through direct development or partnerships, with revenue coming from therapy sales, licensing, and collaborations. The company focuses on research and development to translate human genetics insights into treatments, working with healthcare providers, patients, and academic partners. Overall, Korro Bio seeks to move RNA editing toward real therapies that can help patients around the world by offering precise, targeted interventions at the RNA level.

Company Size

51-200

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2019

Get referred to Korro Bio

See people who can refer or advise you

Simplify's Take

What believers are saying

June 30, 2026 cash reached $137.9 million, funding operations into H2 2028.
KRRO-121 remains on track for first-in-human trials in H2 2026.
March 2026 PIPE and KRRO-111 expanded Korro’s pipeline and sustained investor backing.

What critics are saying

KRRO-110 failed in November 2025, forcing a 34% workforce cut and strategy reset.
Novo Nordisk collaboration paused in November 2025, eliminating collaboration revenue in Q2 2026.
KRRO-121 IND rejection in H2 2026 would leave Korro with no clinical asset.

What makes Korro Bio unique

OPERA edits native mRNA with transient single-base precision, not permanent DNA cuts.
Korro’s GalNAc delivery targets liver tissue through precedented subcutaneous oligonucleotide chemistry.
KRRO-121 combines RNA editing with EMA orphan designation for urea cycle disorders.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
401(k) Retirement Plan
401(k) Company Match
Company Equity

Growth & Insights and Company News

6 month growth

-6%

1 year growth

-5%

2 year growth

TMCnet

Oct 16th, 2026

Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) TMCnet News [October 16, 2026] | / | Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Oct. 16, 2026 (GLOBE NEWSWIRE) - Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA(R) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced the grant of non-statutory stock options to two newly hired employees. Korro granted the new employees nonstatutory stock options to purchase 4,000 shares of Korro's common stock, in the aggregate, at an exercise price of $8.88 per share, the closing price per share of Korro's common stock as reported by Nasdaq on the grant effective date, October 14, 2026. The options each have a ten-year term and vest over four years, with 25% of the shares vesting on the first anniversary of each such employee's applicable start date and the remaining 75% vesting in 36 equal monthly installments on each monthly anniversary thereafter until the fourth anniversary of such employee's applicable start date, subject to the employee's continued service with Korro through each applicable vesting date. These grants were approved by Korro's independent Compensation Committee pursuant to Korro's 2026 Inducement Plan and were made as an inducement material to the employee's acceptance of employmnt with Korro in accordance with Nasdaq Listing Rule 5635(c)(4). About Korro Korro is a clinical-stage biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA(R) platform to develop a new class of genetic medicines for rare and highly prevalent diseases. OPERA provides precise, tissue-directed delivery of RNA-editing oligonucleotides (REOs) that modify the targeted native mRNA transcript to repair or form a de novo protein with enhanced functionality. The platform combines a suite of capabilities consisting of sophisticated knowledge of transcription biology through ADAR proteins (Adenosine Deaminases Acting on RNA), machine learning optimization of REOs, linker chemistry expertise, along with use of a highly targeted tissue-specific delivery methodology. As such, the OPERA platform has enabled Korro to generate and advance a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process, providing precise yet transient single base edits to produce therapeutic proteins with augmented activity versus its endogenous counterpart. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an REO-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary OPERA platform with precedented delivery modalities, including N-acetylgalactosamine (GalNAc) conjugated for delivery for subcutaneous administration, manufacturing know-how, and established regulatory pathways of approved oligonucleotide medicines. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com. Korro Bio Contact Information Investor & Media Contact Malini Chatterjee, Ph.D Blueprint Life Science Group [email protected] or [email protected] 917.330.4269 [ Back To TMCnet.com's Homepage] |

GlobeNewswire

Aug 14th, 2026

Korro Bio reports inducement grant under Nasdaq Listing Rule 5635(c)(4).

Korro Bio reports inducement grant under Nasdaq Listing Rule 5635(c)(4). CAMBRIDGE, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) - Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA(R) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced the grant of a non-statutory stock option to one newly hired employee. Korro granted the new employee a nonstatutory stock option to purchase 600 shares of Korro's common stock at an exercise price of $13.35 per share, the closing price per share of Korro's common stock as reported by Nasdaq on the grant effective date, August 12, 2026. The option has a ten-year term and vests over four years, with 25% of the shares vesting on the first anniversary of the employee's start date and the remaining 75% vesting in 36 equal monthly installments on each monthly anniversary thereafter until the fourth anniversary of the employee's start date, subject to the employee's continued service with Korro through each applicable vesting date. This grant was approved by Korro's independent Compensation Committee pursuant to Korro's 2026 Inducement Plan and was made as an inducement material to the employee's acceptance of employment with Korro in accordance with Nasdaq Listing Rule 5635(c)(4). About Korro Korro is a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA(R) platform to develop a new class of genetic medicines for rare and highly prevalent diseases. OPERA provides precise, tissue-directed delivery of oligonucleotides that modify the targeted native mRNA transcript to repair or form a de-novo protein with enhanced functionality. The platform combines a suite of capabilities consisting of sophisticated knowledge of transcription biology through ADAR proteins (Adenosine Deaminases Acting on RNA), machine learning optimization of oligonucleotides, linker chemistry expertise, along with use of a highly targeted tissue-specific delivery methodology. As such, the OPERA platform has enabled Korro to generate and advance a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process, providing precise yet transient single base edits to produce therapeutic proteins with augmented activity versus its endogenous counterpart. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary OPERA platform with precedented delivery modalities, including N-acetylgalactosamine (GalNAc) conjugated for delivery for subcutaneous administration, manufacturing know-how, and established regulatory pathways of approved oligonucleotide medicines. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com. Korro Bio Contact Information Investor & Media Contact Malini Chatterjee, Ph.D Blueprint Life Science Group [email protected] or [email protected] 917.330.4269

MarketBeat

Aug 8th, 2026

Korro Bio (NASDAQ:KRRO) releases quarterly earnings results, beats expectations by $0.22 EPS.

Korro Bio (NASDAQ:KRRO) releases quarterly earnings results, beats expectations by $0.22 EPS. August 8, 2026 Key points. * Korro Bio beat quarterly earnings expectations: The clinical-stage biotech reported a loss of $1.07 per share, $0.22 better than analysts' forecast, while revenue of $1.50 million exceeded expectations of $0.21 million. However, it posted a negative 1,834.48% net margin and negative 118.45% return on equity. * Shares rose but remain highly volatile: KRRO gained $1.13 to $13.25, compared with a 52-week range of $5.20 to $55.89. Analysts maintain a "Moderate Buy" consensus with a $16.71 average price target. * Insiders have been selling shares: Company insiders sold 306,026 shares worth approximately $4.31 million over the past 90 days, while institutional investors and hedge funds own 13.18% of the stock. * Five stocks to consider instead of Korro Bio. Korro Bio (NASDAQ:KRRO - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($1.07) earnings per share for the quarter, topping the consensus estimate of ($1.29) by $0.22, FiscalAI reports. The company had revenue of $1.50 million for the quarter, compared to analysts' expectations of $0.21 million. Korro Bio had a negative return on equity of 118.45% and a negative net margin of 1,834.48%. Korro Bio price performance. Shares of NASDAQ:KRRO traded up $1.13 during trading hours on Friday, hitting $13.25. 120,198 shares of the company's stock traded hands, compared to its average volume of 159,064. The business has a fifty day moving average price of $12.19 and a 200-day moving average price of $12.06. Korro Bio has a 1 year low of $5.20 and a 1 year high of $55.89. The firm has a market capitalization of $191.06 million, a P/E ratio of -1.32 and a beta of 3.04. Analyst ratings changes. KRRO has been the topic of a number of analyst reports. Lifesci Capital raised Korro Bio to a "strong-buy" rating in a research report on Friday, May 29th. JonesTrading upgraded Korro Bio from a "hold" rating to a "strong-buy" rating in a research note on Friday, May 8th. HC Wainwright reduced their price objective on Korro Bio from $20.00 to $15.00 and set a "buy" rating for the company in a research note on Tuesday, May 19th. Wall Street Zen upgraded shares of Korro Bio from a "strong sell" rating to a "sell" rating in a research note on Saturday. Finally, Citigroup assumed coverage on Korro Bio in a report on Monday, May 18th. They set a "buy" rating and a $21.00 price target on the stock. Three investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $16.71. Insider activity at Korro Bio. In related news, Director Jean Francois Formela sold 9,323 shares of the business's stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $13.96, for a total value of $130,149.08. Following the completion of the transaction, the director owned 146,305 shares of the company's stock, valued at $2,042,417.80. The trade was a 5.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Ram Aiyar sold 15,152 shares of the stock in a transaction on Friday, May 29th. The shares were sold at an average price of $12.98, for a total value of $196,672.96. Following the sale, the chief executive officer directly owned 74,848 shares in the company, valued at $971,527.04. This trade represents a 16.84% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 306,026 shares of company stock valued at $4,309,637 over the last ninety days. Company insiders own 4.80% of the company's stock. Institutional inflows and outflows. Hedge funds have recently added to or reduced their stakes in the business. Nantahala Capital Management LLC purchased a new stake in shares of Korro Bio during the fourth quarter valued at $4,806,000. TCG Crossover Management LLC purchased a new stake in shares of Korro Bio in the third quarter worth about $19,937,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Korro Bio during the 3rd quarter worth approximately $4,319,000. Raymond James Financial Inc. grew its position in Korro Bio by 78.6% during the third quarter. Raymond James Financial Inc. now owns 148,971 shares of the company's stock valued at $7,134,000 after buying an additional 65,579 shares during the period. Finally, F m Investments LLC acquired a new stake in shares of Korro Bio during the 3rd quarter valued at about $2,646,000. 13.18% of the stock is owned by institutional investors and hedge funds. Korro Bio company profile. Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company's proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases. The company's pipeline features both engineered enzyme therapeutics and live biotherapeutics. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Korro Bio, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Korro Bio wasn't on the list. While Korro Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge - and the key risks investors should watch as the global AI buildout accelerates.

Maeil Business Newspaper

Mar 9th, 2026

Korro Bio raises $85M PIPE to fund operations through H2 2028

Korro Bio has raised $85 million through a private investment in public equity (PIPE) round led by new investor Bainrock Healthcare Capital Partners. The company issued 4.5 million ordinary shares at $11.11 per share and 3.1 million pre-funded warrants at $11.109 per share. Combined with $85.2 million in cash and cash equivalents as of 31 December 2025, the funding extends Korro Bio's cash runway through the second half of 2028. The capital will accelerate development of its RNA editing platform OPERA, including clinical programmes KRRO-121 and a GalNAc-conjugated oligonucleotide for alpha-1 antitrypsin deficiency. Citigroup, Cantor, Oppenheimer and William Blair served as placement agents. Analysts forecast continued losses through 2027 despite projected revenue growth.

Investing.com